Drug intelligence / Profile preview

Bitong Capsule

Development stage: Unknown
Lead developer: PT Sinar Herba Radix
Modality: Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Oral

Overview

Bitong Capsule is a traditional Chinese medicine (TCM) developed by Jinan Kangzhong Pharmaceutical Technology Development Co., Ltd. for the treatment of allergic rhinitis. It is formulated as an oral capsule and has undergone Phase I clinical evaluation in China to assess its safety, tolerability, and pharmacokinetic profile in healthy volunteers. As a botanical-based therapy, it is designed to alleviate symptoms of nasal congestion and inflammation associated with allergic rhinitis through the synergistic action of its herbal components.

Brand names: Bitong Capsule

Beyond the preview

Go deeper on Bitong Capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bitong Capsule.

Explore the full profile